Quizartinib Becomes SOC Option in Newly Diagnosed AML With FLT3 ITD Mutation
Quizartinib added to induction and consolidation chemotherapy and continued as a single agent for up to 36 cycles improves the overall survival of adults with FLT3 ITD mutated AML.
Source: targetedonc.com